Pharmacology: Pharmacodynamics: Chlorpromazine has depressant actions on the Central Nervous System, with alpha-adrenergic blocking and anticholinergic activities. It inhibits Dopamine and Prolactin release-inhibitor factor, thus stimulating the release of Prolactin. It increases the turnover of Dopamine in the brain.
It has anti-emetic, anti-pruritic, serotonin-blocking and weak anti-histamine properties and slight ganglion blocking activity. It inhibits the heat regulating centre in the brain, and is analgesic and can relax skeletal muscle.
Due to its action on the autonomic system it produces vasodilatation, hypotension and tachycardia.
Salivary and gastric secretions are reduced.
Pharmacokinetics: Chlorpromazine is readily absorbed in the gastro-intestinal tract. It is subject to first pass metabolism in the gut wall. It is extensively metabolised in the liver and excreted in the urine and faeces. The plasma half-life is only a few hours but it has a prolonged terminal elimination phase of up to about 3 weeks. Chlorpromazine is extensively bound to plasma proteins.
Other Services
Country
Account